Condition

Prostate Adenocarcinoma clinical trials and research

• 51Clinical trials
• 2NIH research projects
• 14Countries

Newest Prostate Adenocarcinoma clinical trials

All recruiting trials (51)

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• Next-generation SABR for prostate cancer across Ireland

  This test uses focused high-dose stereotactic radiotherapy (SABR) with urethra-sparing, a rectal spacer, and nerve preservation for men with low-, intermediate-, or selected high-risk prostate cancer to try to control the tumor while reducing side effects.

  Recruiting at 2 sites Phase 2 Cancer Trials Ireland · Dublin, Leinster and 3 other locations · NCT07552168

• Focal HDR-Brachytherapy for Prostate Cancer

  This trial tests using targeted high-dose-rate brachytherapy to treat prostate cancer patients and see if it provides local control with fewer side effects.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07468903

• Shorter androgen deprivation in combination with radiation for high-risk prostate cancer

  Doctors are testing whether 6 months of hormone therapy with radiation works as well as 18 months, for men with high-risk prostate cancer.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT07364071

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• Relugolix to improve PSMA PET/CT imaging in men with high or very high risk prostate cancer

  We are testing whether a short course of relugolix can boost PSMA levels and make PSMA PET/CT scans better at finding cancer in men with high or very high risk prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT07025369

• Detecting double-positive (tumor marker/CD45+) cells in the blood of people with metastatic cancer

  This one-day study will test two blood-based methods to find double-positive tumor/CD45+ circulating cells in adults who are about to start treatment for various metastatic cancers.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06967961

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• Adaptive SBRT to para‑aortic and iliac lymph nodes to help prostate cancer responses last longer.

  This study will try CT-guided, online adaptive SBRT to the tumor and nearby at-risk lymph nodes to see if men with oligorecurrent para‑aortic or common iliac nodal prostate cancer get longer-lasting control.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06831032

• Investigational scan for detecting recurrent prostate cancer

  This study is testing a new imaging technique to see if it can help find prostate cancer in men whose PSA levels are rising after treatment but who had a negative result on their last scan.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT06813898

• Using Lu-177-PSMA-617 before surgery for high-risk localized prostate cancer

  This study is testing if a new treatment called Lu-177-PSMA-617 can help men with high-risk localized prostate cancer before they have surgery.

  Recruiting Phase 2 Hackensack Meridian Health · Washington D.C., District of Columbia and 2 other locations · NCT06798558

• Recurrence-directed therapy with or without 12 months of androgen-deprivation (ELIGARD) for radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer

  This will test whether adding 12 months of ELIGARD® (androgen-deprivation therapy) to recurrence-directed radiotherapy helps men with radio-recurrent oligo-metastatic, hormone-sensitive prostate cancer stay progression-free longer.

  Recruiting at 4 sites Phase 2 Ontario Clinical Oncology Group (OCOG) · Hamilton, Ontario and 4 other locations · NCT06654336

• Two-fraction radiotherapy for localized prostate cancer

  This study is testing if giving radiotherapy in just two sessions instead of five can effectively treat localized prostate cancer while causing fewer side effects for patients.

  Recruiting UMC Utrecht · Utrecht · NCT06518226

• Combining relugolix and enzalutamide with radiation therapy for very high risk prostate cancer

  This study is testing if combining two medications, relugolix and enzalutamide, with radiation therapy can help men with very high risk prostate cancer live longer and feel better.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT06499870

• Using ICG to improve sexual function outcomes after prostate surgery

  This study is testing whether using a special dye during prostate surgery can help improve sexual function for men after their operation.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT06446648

• Radiation therapy for recurrent prostate cancer

  This study is testing a new way to use radiation therapy for men with recurrent prostate cancer to see if it helps control the cancer better while also keeping their quality of life intact.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06392295

• Comparing the effects of relugolix and leuprolide on heart health in prostate cancer patients

  This study is testing whether relugolix or leuprolide is better for heart health in men with prostate cancer who are also getting radiation treatment.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06330805

• Understanding how obesity-related factors influence prostate cancer progression

  This study looks at how being overweight or obese affects prostate cancer by checking certain enzymes and immune cells in tumor samples from patients with different body weights.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT06292897

• Local delivery of enzalutamide implants for prostate cancer treatment

  This study is testing a new implant that delivers a prostate cancer drug directly to the prostate to see if it is safe and well-tolerated by patients before surgery.

  Recruiting at 10 sites Phase 1 Alessa Therapeutics Inc. · Fresno, California and 9 other locations · NCT06257693

• Comparing two robotic surgery methods for prostate cancer treatment

  This study is testing which of two robotic surgery methods works better for treating localized prostate cancer and helps patients recover faster.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06238713

• Reducing bowel side effects by changing proton beam spot placement for prostate cancer

  This will test whether deleting proton beam spots near the rectum and small bowel during pencil-beam proton therapy lowers bowel and bladder side effects in men with low- or intermediate-risk prostate cancer.

  Recruiting Covenant Health Cancer Center · Knoxville, Tennessee · NCT06200259

• Using blood tests to predict treatment response in advanced prostate cancer

  This study is testing if blood tests can help predict how well men with advanced prostate cancer will respond to their treatment.

  Recruiting at 3 sites Duke University · New York, New York and 2 other locations · NCT06141993

• Hormone therapy and targeted radiation for prostate cancer treatment

  This study is testing if combining a hormone therapy that blocks testosterone with targeted radiation can help men with prostate cancer see better results and improve their quality of life.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT06067269

• Using PSMA PET imaging to guide targeted radiation therapy for high-risk prostate cancer

  This study tests if using PSMA PET imaging to time radiation therapy better can help improve treatment for people with high-risk prostate cancer.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas and 1 other locations · NCT06044857

• Urolithin A supplementation for men with prostate cancer before surgery

  This study is testing if taking Urolithin A before surgery can help men with prostate cancer by reducing stress in their tumor tissue.

  Recruiting at 5 sites Phase 2 National Cancer Institute (NCI) · Los Angeles, California and 4 other locations · NCT06022822

• Personalized biopsy approach for prostate cancer diagnosis

  This study tests a new way to take fewer biopsy samples for diagnosing prostate cancer to see if it can still accurately find the disease while reducing complications.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT05998278

• Evaluating BL-B01D1 for patients with advanced lung and solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced lung cancer and other solid tumors.

  Recruiting at 37 sites Phase 1 SystImmune Inc. · Beverly Hills, California and 36 other locations · NCT05983432

• Comparing shorter radiation therapy to standard radiation for high-risk prostate cancer

  This study is testing if a shorter, more intense radiation treatment for high-risk prostate cancer can work just as well as the standard longer treatment.

  Recruiting at 431 sites Phase 3 NRG Oncology · Birmingham, Alabama and 435 other locations · NCT05946213

• Comparing surgery and radiation for high-risk prostate cancer

  This study is testing whether surgery or radiation works better for men with high-risk prostate cancer and how each treatment affects their quality of life and health outcomes.

  Recruiting at 24 sites Comprehensive Cancer Centre The Netherlands · Alkmaar and 27 other locations · NCT05931419

• Evaluating PSMA Changes in Prostate Cancer After Hormonal Therapy

  This study is testing how hormonal therapy changes a specific protein in men with prostate cancer to see if those changes can help doctors understand the cancer better.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT05919329

• Using advanced imaging to detect prostate cancer in men eligible for active surveillance

  This study is testing a new type of imaging to see if it can better find serious prostate cancer in men who are being monitored for low-risk disease.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT05852041

• Using a fasting-mimicking diet to improve prostate cancer control and metabolic health

  This study is testing if a special fasting-mimicking diet can help men with advanced prostate cancer feel better and improve their overall health while they receive standard treatment.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Duarte, California and 2 other locations · NCT05832086

• Carboplatin treatment before surgery for high-risk prostate cancer with BRCA mutations

  This study is testing if giving carboplatin chemotherapy before surgery can help men with high-risk prostate cancer and BRCA mutations have better outcomes.

  Recruiting at 132 sites Phase 2 SWOG Cancer Research Network · Anchorage, Alaska and 132 other locations · NCT05806515

• Effects of exercise therapy on prostate cancer indicators

  This study is testing if a home-based walking program can help men with low-risk prostate cancer show better signs of their condition compared to those who stick to their usual exercise routines.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 9 other locations · NCT05751434

• Combining Enzalutamide and Relacorilant for High-risk Localized Prostate Cancer

  This study is testing whether combining two drugs, enzalutamide and relacorilant, with hormone therapy can help improve treatment outcomes for men with advanced, high-risk localized prostate cancer before surgery.

  Recruiting at 3 sites Phase 2 University of Chicago · Chicago, Illinois and 3 other locations · NCT05726292

• Reducing radiation doses in prostate cancer treatment using advanced technology

  This study is testing whether using advanced technology can safely lower radiation doses in men with intermediate risk prostate cancer while still keeping their PSA levels under control.

  Recruiting Royal Marsden NHS Foundation Trust · Sutton, Surrey · NCT05709496

• High dose rate brachytherapy for localized prostate cancer

  This study is testing a new way to give high dose rate brachytherapy to treat localized prostate cancer in two sessions to see if it's safe for patients with low to intermediate risk.

  Recruiting University of California, San Francisco · San Francisco, California · NCT05665738

• Focal therapy using SBRT for single prostate tumors

  This study is testing whether a targeted radiation treatment can effectively shrink single prostate tumors in men with localized prostate cancer while causing fewer side effects than standard treatments.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05616650

• Comparing single-port robotic prostate surgery to high-intensity focused ultrasound for prostate cancer

  This study is testing whether single-port robotic surgery or high-intensity focused ultrasound is better for treating localized prostate cancer in men with low to intermediate risk.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT05610852

• Comparing two versus five MRI-guided treatments for prostate cancer

  This study is testing if giving radiation treatment for prostate cancer in just two sessions instead of five can work just as well for men with localized prostate cancer.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05600400

• Using ultrasound to assess erectile dysfunction after prostate cancer surgery

  This study is testing a new ultrasound method to see if it can help men recover their erectile function after prostate cancer surgery.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT05109208

• Evaluating PSMA-PET/CT for Prostate Cancer Recurrence

  This study is testing if using a special imaging technique called PSMA-PET/CT can help guide better treatment for men with prostate cancer who have had a rise in their PSA levels after surgery.

  Recruiting Azienda Ospedaliero-Universitaria Careggi · Florence · NCT05022914

• Registry for patients undergoing TULSA procedure for prostate conditions

  This study is tracking patients who have had the TULSA procedure for prostate issues to see how safe and effective it is and how it affects their quality of life over time.

  Recruiting at 5 sites Profound Medical Inc. · West Hills, California and 4 other locations · NCT05001477

• Combining high dose-rate brachytherapy and stereotactic body radiotherapy for prostate cancer treatment

  This study is testing whether combining two types of radiation therapy can improve treatment outcomes for men with prostate cancer.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT04945642

• Combining Bipolar Androgen Therapy with Radium-223 for advanced prostate cancer

  This study is testing whether combining a new hormone treatment with a radiation therapy can help men with advanced prostate cancer feel better and improve their health.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland and 1 other locations · NCT04704505

• Combining Apalutamide and Targeted Radiation for Recurrent Prostate Cancer

  This study is testing if combining a new medication with radiation therapy can help men with recurring prostate cancer feel better and live longer after surgery.

  Recruiting at 278 sites Phase 3 Eastern Cooperative Oncology Group · Anchorage, Alaska and 340 other locations · NCT04423211

• Site-directed therapy using PSMA or FACBC PET/CT for prostate cancer treatment

  This study is testing if using special imaging techniques to guide targeted treatments can help men with prostate cancer get better results from their therapy.

  Recruiting at 2 sites Phase 2 University of Washington · Pittsburgh, Pennsylvania and 1 other locations · NCT04175431

• Monitoring prostate cancer with advanced MRI techniques

  This study is testing a new type of MRI to see if it can better track prostate cancer in patients who are being watched closely and how it relates to their biopsy results.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT03933670

• Nutrition and exercise interventions for prostate cancer survivors

  This study tests whether personalized nutrition and exercise plans can help prostate cancer survivors feel stronger and healthier while they are receiving hormone therapy.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT03880422

• Atezolizumab-based therapy for men with localized prostate cancer before surgery

  This study is testing a new immunotherapy treatment for men with localized prostate cancer to see if it helps their immune system fight the cancer before they have surgery.

  Recruiting at 2 sites Phase 2 University of California, San Francisco · San Francisco, California and 1 other locations · NCT03821246

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Immune and tumor environment factors driving prostate cancer progression and response to androgen deprivation

  A large NIH grant is exploring how immune cells and the tumor environment affect prostate cancer growth and response to androgen-suppressing treatments.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11312664

• Understanding how immune and stromal factors affect prostate cancer progression and treatment response

  This study is looking at how prostate cancer cells interact with their surroundings, especially the immune system and other supporting cells, to better understand how the disease grows and responds to treatments, which could help create more personalized and effective therapies for patients.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11078868

Related topics

Quick answers

How many Prostate Adenocarcinoma clinical trials are recruiting right now?

51, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in United States (39 trials), Canada (4 trials), Italy (3 trials), Netherlands (2 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 23, Phase 1: 3, Early Phase 1: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →